Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Biologics technology transfer (tech transfer) requires close coordination across every step, from initial process definition, subsequent analytical interpretation, and cross-facility execution.

The current discussion of downstream bottlenecks arises from the ease with which up-stream activities generate protein and the desire for downstream operations to match upstream productivity. “In ...